This study aims to assess the treatment effects of the molecular adsorbent recirculating system (MARS) in @entity1 with @entity879 . We searched MEDLINE, EMBASE, and the Cochrane Controlled Trials Registry database between January 1966 and January 2014. We included randomized controlled trials, which compared the treatment effects of MARS with standard medical treatment. Study quality assessed according to Consolidated Standards of Reporting Trials (CONSORT) criteria. The risk ratio was used as the effect-size measure according to a fixed-effects model. The search strategy revealed 72 clinical studies, 10 of which were randomized controlled trials that met the criteria and were included. Four addressed ALF (93 @entity1 ) and six addressed AOCLF (453 @entity1 ). The mean CONSORT score was 15 (range 10-20). By meta-analysis, MARS significantly improved survival in ALF (risk ratio 0.61; 95% CI 0.38, 0.97; P = 0.04). There was no significant survival benefit in AOCLF (risk ratio 0.88; 95% CI 0.74, 1.06; P = 0.16). MARS significantly improved survival in @entity1 with @entity879 , however, there is no evidence that it improved survival in @entity1 with @entity879 . In conclusion, the present meta-analysis indicates that MARS therapy can improve survival in @entity1 with ALF. It is necessary to develop MARS treatment because of the increasing demand for liver transplantation and the risk of @entity1578 .

Meta-analysis of survival with the molecular adsorbent recirculating system for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity879 :: ('MESH:D017114', 'Disease') :: ['acute-on-chronic liver failure', 'acute liver failure', 'acute and acute-on-chronic liver failure'] @entity1578 :: ('MESH:D017093', 'Disease') :: ['liver failure']
@entity1578 :: (MESH:D017093,Disease) :: ['liver failure']
